Oslo, Norway, April 10, 2024 - EXACT Therapeutics AS (Euronext Growth: EXTX), a
clinical stage precision health company utilising Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, presented a poster at the prestigious
annual meeting of the American Association for Cancer Research (AACR) on April
9. 

Dr. Udai Banerji, the principal investigator of the ACTIVATE study and Dr. Amir
Snapir, Chief Medical Officer of EXACT Therapeutics presented the poster
showcasing the results from the dose escalation part of the ACTIVATE study in
patients with liver metastases of colorectal origin.

The main conclusions are: 
o	The results provide proof of concept that treatment with ACT® produces
substantial reduction in tumour size in patients treated with standard of care
chemotherapeutics. 
o	The results do not show any unexpected side effects from ACT on its own or any
worsening of the adverse effects of chemotherapy. 

Dr. Per Walday, CEO of EXACT Therapeutics comments: "The results of the dose
escalation part of the ACTIVATE study are very encouraging, indicating that
targeted treatment with ACT is both safe and effective. This is truly promising
and I would like to thank the team for the great work leading up to this and the
participating patients for their support."  

The ACTIVATE study is on track to be completed in 2024.

The poster is also available here: https://exact-tx.com/publications-1-1 

For more information, please contact: 
Per Walday 
CEO EXACT Therapeutics 
Email: per.walday@exact-tx.com 

About EXACT-Tx: 
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to enable or significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy) and brain
diseases. www.exact-tx.com 


About ACT® 
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
o ACT® is being tested in the clinic and has released positive interim data. It
is supported by a strong and broad preclinical package demonstrating therapeutic
enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as
well as blood-brain barrier penetration. 
o Initial focus of the Company is oncology. The ACT® platform has potential
across many therapeutic areas (including CNS, immunotherapy) and product
classes. 

Forward looking statements: This announcement and any materials distributed in
connection with this announcement may contain certain forward-looking
statements. By their nature, forward-looking statements involve risk and
uncertainty because they reflect the Company's current expectations and
assumptions as to future events and circumstances that may not prove accurate. A
number of material factors could cause actual results and developments to differ
materially from those expressed or implied by this forward-looking statement.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.